Janux Therapeutics (NASDAQ:JANX) Price Target Increased to $53.00 by Analysts at Wedbush

Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its target price hoisted by Wedbush from $24.00 to $53.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 250.99% from the company’s current […]

Related Keywords

Immunomodulator Tracir ,Nisa Investment Advisors ,Cerity Partners ,Sg Americas Securities ,Janux Therapeutics Company Profile ,Unisuper Management Pty Ltd ,Janux Therapeutics Inc ,Janux Therapeutics ,Get Free Report ,Super Management Pty Ltd ,Investment Advisors ,Tumor Activatedt Cell Engager ,Tumor Activated Immunomodulator ,Janux Therapeutics Daily ,Nasdaq Janx ,Janx ,Medical ,Boost Price Target ,Wedbush ,